How to Group Multiple Models for UKCA Registration in the United Kingdom?

How to Group Multiple Models for UKCA Registration in the United Kingdom?

For UKCA registration in the United Kingdom, grouping multiple models into a single application can significantly reduce costs and time. The key requirement is to demonstrate that all models share a common technical platform, have similar intended uses, and that any differences do not affect safety or performance. Models can be considered as a "series" or "family" if they share core technical documentation such as design specifications, materials, sterilization methods, packaging, and shelf life. The justification must be supported by evidence including a model difference matrix, risk analysis for each variant, and representative test reports.

Key Points

Medical devices registered under UKCA can benefit from multi-model grouping. The manufacturer must first determine whether the product falls under medical device regulations and classify it according to risk (e.g., Class I, IIa, IIb, III). Models from the same technical platform with similar intended use and differences that do not impact safety or performance (e.g., different sizes or colors) may be grouped. The core logic is to prove that all models share key technical documents, including design specifications, materials, sterilization methods, packaging, and shelf life. Required documentation includes risk analysis, performance verification, biocompatibility, software validation (if applicable), clinical evaluation (or equivalence justification), labeling, instructions for use, and the UKCA Declaration of Conformity.

Applicable Scenarios and Core Issues

Grouping is common for in vitro diagnostic reagents, implants, surgical instruments, and software. The core issue is how to package multiple models into a single registration to save costs and accelerate market access. Prerequisites include high technical similarity and differences that do not affect safety and effectiveness. For example, different sizes of syringe needles, different volumes of test kits, or different software versions with the same core algorithm. UKCA rules partially overlap with CE, but UKCA places greater emphasis on UK local responsibility and post-market surveillance. Manufacturers must evaluate whether existing CE technical files can be directly used for UKCA or require supplementation with UK-specific requirements (e.g., UKCA marking rules, UK-designated standards).

Registration Decision Logic

First, confirm whether the product is a medical device per UK MDR 2002 (definition similar to EU MDD/MDR, noting separate transitional arrangements for IVDs). Second, determine classification using EU classification rules (Class I, IIa, IIb, III), noting possible changes due to guidance updates. Third, identify the registration route: Class I can be self-declared; Class IIa/IIb/III require notified body review. For grouped models, notified bodies will assess the justification. Assess reuse of existing documentation: NMPA certificates, CE certificates, FDA 510(k), ISO 13485/MDSAP can support evidence, but technical files must be converted to UK format, especially risk management, clinical evaluation, and labeling. If the product already has CE MDR certification, most data can be referenced, but a UK Responsible Person must be appointed and the applicable regulatory statements in the technical file updated. Finally, confirm the grouping strategy: identify a "primary model" with full technical documentation and "derivative models" with only differences described. Notified bodies typically require labeling, IFU samples, and packaging information for each model.

Documents and Evidence

Core documents include: technical file (product description, design, manufacturing process), risk management file (ISO 14971 or EN ISO 14971), performance verification reports (mechanical, electrical, chemical, biocompatibility, software validation), clinical evaluation or clinical data (including equivalence justification), labeling, IFU, packaging, UKCA Declaration of Conformity, and UK Responsible Person (UKRP) agreement. For grouped models, additionally provide:

• Detailed list of all models (model names, specifications, UDI)
• Difference matrix clearly showing similarities and differences and demonstrating that differences do not affect safety or effectiveness
• Risk analysis for each model (at least covering differences)
• Versions of labels and IFUs as applicable (e.g., different languages or markings)
• Representative test reports (e.g., biocompatibility, EMC) with equivalence justification for other models

Common Mistakes

• Forcing models with significant functional or risk differences into the same group (e.g., combining active and passive devices, or models with different intended uses)
• Omitting difference analysis, simply listing model names without technical evidence
• Overlooking UK-specific requirements: UKCA marking size rules, UKRP must be established and operating, registration must be submitted within 12 months of completing conformity assessment
• Not considering PMSF differences: each model may require separate PMSF plans and reports, especially for adverse event reporting
• Poorly defined scope of UKRP: the UKRP must confirm in the registration application which models are covered; failure to update when adding new models can invalidate registration

Company Preparation Checklist

• Confirm product is a medical device and determine classification
• List all models and their technical differences, create difference matrix
• Compile existing NMPA, CE, FDA documentation and assess reusability
• Sign agreement with UKRP defining scope of authorization
• Prepare multi-model technical file including difference analysis and representative testing
• Complete risk management and clinical evaluation (if applicable)
• Design UKCA labels and IFU
• Draft UKCA Declaration of Conformity
• Submit registration application (self-declaration or via notified body)
• Establish PMSF system ensuring all models are covered

AIMEILI Regulatory Interpretation

Companies often mistakenly believe that products in the same category can be arbitrarily grouped. In reality, UKCA notified bodies strictly review the justification for grouping, particularly clinical evaluation. If differences affect clinical safety, separate clinical data may be required. Early in the project, all models should be technically characterized, and a regulatory expert should assess grouping feasibility. For document reuse, CE MDR technical files can generally be converted directly, but note that UKCA risk management definitions (e.g., "reasonably foreseeable misuse" and "severity levels") may differ slightly. Local representation and certificate control are critical: the UKCA registration requires UK local responsibility, and if the UKRP changes or becomes invalid, all models' registrations may be affected. For changes and renewals, all models must be updated simultaneously. For multi-country registrations, core technical documents (risk management, clinical evaluation) should be consistent, but each country requires local adaptation (language, standards, agent). This reduces duplication and avoids deficiencies, as review findings in one country often predict points of focus in others.

Frequently Asked Questions

Q: Can implants of different sizes be grouped?
A: Yes, provided the material, design, and manufacturing process are identical, with only dimensional differences. Mechanical and biocompatibility testing for each size (or worst-case equivalence) must be provided.

Q: What are the special requirements for the UK Responsible Person for grouped submissions?
A: The UKRP must assume legal responsibility for each model and the authorization letter must explicitly list all models. For large groups, coordinate with the UKRP early to ensure they can cover PMSF obligations for all models.

Q: Can a CE certificate covering multiple models be directly referenced for UKCA?
A: CE technical file content can be referenced, but a UKCA-formatted technical file and a declaration of conformity to UK regulations are still required. The CE certificate itself does not replace UKCA registration but may expedite review. Note that UKCA and CE markings cannot be used simultaneously (except during transition), so choose the appropriate route.

Implementation Recommendations

In practice, companies should break down the task into five parts: regulatory determination, document preparation, evidence reuse, local adaptation, and post-market maintenance, rather than assigning temporary document compilation to one department. This identifies gaps early and aligns sales, R&D, quality, and regulatory teams on target country requirements. For multi-market entry, develop a unified core technical file, then supplement with country-specific authorizations, labels, language, forms, and local agent documents. Multi-country registration efficiency depends more on the initial document framework than on the speed of individual country submissions. Confirm product scope under target country medical device regulations. Determine risk classification, registration route, and applicant. Verify that technical files, quality systems, and clinical evidence are mutually supportive. Clarify local agent, authorized representative, and certificate control. Establish mechanisms for post-market changes, renewals, and vigilance.

Published: July 26, 2026